Company research
VYCOR MEDICAL INC
CIK 1424768Updated Oct 6, 2026
SecurityVYCO · OTC · equity
VYCO price & chart
Loading TradingView…
OTC:VYCO on TradingView ↗About the company
With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB:VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.
In the news
No coverage from other publishers is available.
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-K filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 941,195Source | 1,074,604Source | 813,174Source | 878,946Source | 996,972Source | 854,071Source | 940,831Source | 968,792Source | 830,420Source | 998,117Source | 992,298Source | 860,178Source |
| Property, Plant and Equipment, NetUSD | 148,474Source | 209,732Source | 101,373Source | 164,338Source | 220,441Source | 116,128Source | 176,585Source | 236,122Source | 133,936Source | 192,693Source | 252,404Source | 303,770Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 64,230Source | 157,633Source | 158,907Source | 99,700Source | 119,296Source | 173,634Source | 61,049Source | 43,857Source | 86,982Source | 105,648Source | 57,291Source | 37,035Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 326,052Source | 238,700Source | 202,447Source | 202,669Source | 252,776Source | 194,041Source | 229,411Source | 244,069Source | 218,891Source | 245,260Source | 215,231Source | 156,204Source |
| Inventory, NetUSD | 167,415Source | 187,627Source | 190,508Source | 156,033Source | 218,313Source | 181,910Source | 176,373Source | 221,728Source | 159,202Source | 222,189Source | 234,145Source | 248,874Source |
| Assets, CurrentUSD | 662,596Source | 743,430Source | 635,877Source | 554,355Source | 643,494Source | 651,047Source | 600,695Source | 588,180Source | 563,422Source | 695,719Source | 584,090Source | 517,763Source |
| Prepaid Expense and Other Assets, CurrentUSD | 103,474Source | 158,500Source | 83,695Source | 95,690Source | 52,092Source | 101,462Source | 132,994Source | 77,460Source | 97,230Source | 121,705Source | 76,684Source | 74,438Source |
| Operating Lease, Right-of-Use AssetUSD | 67,615Source | 115,442Source | 30,147Source | 79,793Source | 127,037Source | 42,795Source | 91,822Source | 138,490Source | 55,283Source | 103,705Source | 149,804Source | 32,645Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,965,388Source | 4,757,950Source | 5,064,398Source | 4,745,890Source | 4,525,279Source | 5,083,027Source | 4,831,662Source | 4,487,061Source | 4,917,299Source | 4,688,200Source | 4,317,774Source | 3,801,049Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | — | — | — | — | — | — | — | — | — | — | — | 27Source |
| Common Stock, Value, IssuedUSD | 3,347Source | 3,348Source | 3,347Source | 3,347Source | 3,273Source | 3,347Source | 3,347Source | 3,273Source | 3,347Source | 3,347Source | 3,273Source | 3,263Source |
| Additional Paid in CapitalUSD | 29,431,959Source | 29,431,958Source | 29,431,959Source | 29,431,959Source | 29,365,070Source | 29,431,959Source | 29,431,959Source | 29,365,070Source | 29,431,959Source | 29,431,959Source | 29,365,070Source | 29,355,626Source |
| Retained Earnings (Accumulated Deficit)USD | -33,586,170Source | -33,245,323Source | -33,813,221Source | -33,428,921Source | -33,023,321Source | -33,790,933Source | -33,452,808Source | -33,013,283Source | -33,648,856Source | -33,252,060Source | -32,820,490Source | -32,426,429Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 127,677Source | 127,677Source | 127,697Source | 127,677Source | 127,677Source | 127,677Source | 127,677Source | 127,677Source | 127,677Source | 127,677Source | 127,677Source | 127,675Source |
| Stockholders' Equity Attributable to ParentUSD | -4,024,193Source | -3,683,346Source | -4,251,224Source | -3,866,944Source | -3,528,307Source | -4,228,956Source | -3,890,831Source | -3,518,269Source | -4,086,879Source | -3,690,083Source | -3,325,476Source | -2,940,871Source |
| Liabilities and EquityUSD | 941,195Source | 1,074,604Source | 813,174Source | 878,946Source | 996,972Source | 854,071Source | 940,831Source | 968,792Source | 830,420Source | 998,117Source | 992,298Source | 860,178Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,815,077Source | 4,552,889Source | 4,930,420Source | 4,581,539Source | 4,307,234Source | 4,948,048Source | 4,653,574Source | 4,256,317Source | 4,781,468Source | 4,496,543Source | 4,074,487Source | 3,654,796Source |
| Operating Lease, Liability, CurrentUSD | 51,179Source | 47,178Source | 26,700Source | 50,157Source | 46,466Source | 39,540Source | 49,151Source | 45,890Source | 52,221Source | 48,158Source | 45,321Source | 29,591Source |
| Accounts Payable, CurrentUSD | 92,821Source | 150,980Source | 111,784Source | 110,042Source | 154,770Source | 90,467Source | 165,151Source | 147,859Source | 84,755Source | 147,569Source | 117,801Source | 200,044Source |
| Operating Lease, Liability, NoncurrentUSD | 13,566Source | 64,745Source | — | 26,700Source | 76,857Source | — | 39,540Source | 88,692Source | — | 52,221Source | 100,379Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 127,231Source | — | 94,354Source | — | — | 90,953Source | — | — | 89,938Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | 18,315Source | 48,838Source | 26,783Source | 10,141Source | 185,610Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -16,510Source | -15,846Source | -23,678Source | 33,404Source | 59,027Source | 30,108Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -10,970Source | 19,913Source | 8,792Source | -11,956Source | -14,729Source | 56,868Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 5,712Source | 17,582Source | -62,813Source | 29,768Source | -82,243Source | -27,676Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 99,422Source | -26,909Source | -13,471Source | 60,110Source | 29,430Source | -217,016Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 2,140Source | — | -4,383Source | -4,199Source | -9,386Source | -2,780Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 5,224Source | 4,199Source | 9,386Source | 2,780Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -14,910Source | -17,690Source | -812Source | -7,554Source | 211Source | 165,889Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 86,652Source | -44,599Source | -18,666Source | 48,357Source | 20,256Source | -53,906Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,305Source | 2,233Source | 21,196Source | 40,504Source | 5,550Source | 8,246Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 0Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 0Source | — | 0Source | — | 2,364Source | — | 2,364Source | — | — |
| DepreciationUSD | — | — | — | — | — | — | 15,668Source | 16,110Source | 63,143Source | 63,910Source | 60,752Source | 61,403Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -640Source | -103Source | -126Source | 1Source | -4Source | 1Source | -508Source | -230Source | -206Source | -964Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 4,990Source | -59,770Source | -19,109Source | 25,713Source | 20,095Source | -38,514Source | -70,190Source | -106,951Source | -63,080Source | -399,705Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -54Source | -47Source | -3,179Source | -1,826Source | 13Source | -49Source | -2,236Source | -249Source | -6,611Source | -5,212Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | — | 17,211Source | — | 15,515Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 4,936Source | -59,817Source | -22,288Source | 23,887Source | 20,108Source | -38,563Source | -72,426Source | -107,200Source | -69,691Source | -404,917Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -157,249Source | -222,002Source | -22,288Source | 23,887Source | -142,077Source | -200,748Source | -396,796Source | -431,570Source | -394,061Source | -729,287Source |
| Nonoperating Income (Expense)USD | — | — | -27,095Source | -24,635Source | -25,960Source | -25,433Source | -25,713Source | -25,708Source | -104,090Source | -97,806Source | -103,271Source | -93,191Source |
| Operating ExpensesUSD | — | — | 419,847Source | 389,191Source | 337,594Source | 364,125Source | 329,345Source | 371,340Source | 1,527,207Source | 1,431,660Source | 1,275,463Source | 1,388,859Source |
| Amortization | — | — | —Source | —Source | — | —Source | — | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 513,792Source | 390,852Source | 418,264Source | 496,353Source | 458,540Source | 436,378Source | 1,863,400Source | 1,589,324Source | 1,460,604Source | 1,222,989Source |
| Cost of RevenueUSD | — | — | 61,860Source | 36,796Source | 73,819Source | 81,082Source | 83,387Source | 77,844Source | 302,293Source | 166,809Source | 144,950Source | 140,644Source |
| Selling, General and Administrative ExpenseUSD | — | — | 404,967Source | 367,886Source | 322,711Source | 345,043Source | 315,365Source | 350,698Source | 1,457,723Source | 1,356,814Source | 1,195,408Source | 1,330,627Source |
| Operating Income (Loss)USD | — | — | 32,085Source | -35,135Source | 6,851Source | 51,146Source | 45,808Source | -12,806Source | 33,900Source | -9,145Source | 40,191Source | -306,514Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 4,990Source | -59,770Source | -19,109Source | 25,713Source | 20,095Source | -38,514Source | -70,190Source | -106,951Source | -63,080Source | -399,705Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 4,936Source | -59,817Source | -22,288Source | 23,887Source | 20,108Source | -38,563Source | -72,426Source | -107,200Source | -69,691Source | -404,917Source |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | -0.01Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | -0.01Source | -0.01Source | -0.02Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | -0.01Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | -0.01Source | -0.01Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 33,372,796Source | 32,903,493Source | 33,372,796Source | 33,372,796Source | 33,372,796Source | 33,372,796Source | 33,372,796Source | 32,884,882Source | 32,603,767Source | 31,708,076Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 33,372,796Source | 32,903,493Source | 33,372,796Source | 38,667,862Source | 33,372,796Source | 33,372,796Source | 33,372,796Source | 32,884,882Source | 32,603,767Source | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 14,880Source | 14,880Source | 14,883Source | 14,881Source | 13,980Source | 14,880Source | 59,521Source | 59,521Source | 57,497Source | 58,232Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -640Source | -103Source | -126Source | 1Source | -4Source | 1Source | -508Source | -230Source | -206Source | -964Source |
| Gross ProfitUSD | — | — | 451,932Source | 354,056Source | 344,445Source | 415,271Source | 375,153Source | 358,534Source | 1,561,107Source | 1,422,515Source | 1,315,654Source | 1,082,345Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -44,630Source | -81,834Source | -42,829Source | -382,553Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 4,990Source | -59,770Source | -19,109Source | 25,713Source | 20,095Source | -38,514Source | -70,190Source | -106,951Source | -63,080Source | -399,705Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | 0Source | -0.01Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | -0.01Source | 0Source | -0.01Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | 0Source | -0.01Source | 0Source | 0Source | 0Source | -0.01Source | -0.01Source | -0.01Source | 0Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -54Source | -47Source | -3,179Source | -1,826Source | 13Source | -49Source | -2,236Source | -249Source | -6,611Source | -5,212Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -157,249Source | -222,002Source | -22,288Source | 23,887Source | -142,077Source | -200,748Source | -396,796Source | -431,570Source | -394,061Source | -729,287Source |
| Nonoperating Income (Expense)USD | — | — | -27,095Source | -24,635Source | -25,960Source | -25,433Source | -25,713Source | -25,708Source | -104,090Source | -97,806Source | -103,271Source | -93,191Source |
| Operating ExpensesUSD | — | — | 419,847Source | 389,191Source | 337,594Source | 364,125Source | 329,345Source | 371,340Source | 1,527,207Source | 1,431,660Source | 1,275,463Source | 1,388,859Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | — | — | 3,081,515Source | 2,757,145Source | 2,919,330Source | 2,594,960Source | 2,270,590Source | 1,946,220Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | 162,185Source | 162,185Source | — | — | 162,185Source | 162,185Source | 324,370Source | 324,370Source | 324,370Source | 324,370Source |
| Research and Development ExpenseUSD | — | — | — | 6,425Source | — | 4,201Source | — | 5,762Source | 9,963Source | 15,325Source | 22,558Source | — |
Filing attachments
ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three And Six Months Ended June 30, 2026 BOCA RATON, FL (August 14, 2026) - Vycor Medical, Inc. (“Vycor”) (OTCQB - VYCO), today announced financial results for the three and six months ended June 30, 2026. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision ®, a business in development which offers …
Read attachment ↗ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three Months Ended March 31, 2026 BOCA RATON, FL (May 15, 2026) - Vycor Medical, Inc. (“Vycor”) (OTCQB - VYCO), today announced financial results for the three months ended March 31, 2026. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision ®, a business in development which offers therapy programs …
Read attachment ↗ex99-1.htm · 8-K · 2026-03-31
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the for the Year Ended December 31, 2025 BOCA RATON, FL (March 31, 2026) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the year ended December 31, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision ®, a business in development which offers t…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-14
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three and Nine Months Ended September 30, 2025 BOCA RATON, FL (November 14, 2025) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the three and nine months ended September 30, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision ®, a busines…
Read attachment ↗ex99-1.htm · 8-K · 2025-08-08
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2025 BOCA RATON, FL (August 8, 2025) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the three and six months ended June 30, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision ®, a business in developmen…
Read attachment ↗ex99-1.htm · 8-K · 2025-05-15
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Vycor Medical Releases Financial Results for the Three Months Ended March 31, 2025 BOCA RATON, FL (May 15, 2025) - Vycor Medical, Inc. (“Vycor” or the “Company”) (OTCQB - VYCO), today announced financial results for the three months ended March 31, 2025. The company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgery; and NovaVision®, a business in development which offers th…
Read attachment ↗